NEW YORK, Jan. 25, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against PixarBio Corporation (“PixarBio” or the “Company”) (OTC:PXRB) in the United States District Court for the District of New Jersey on behalf of purchasers of PixarBio (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for PixarBio investors under the federal securities laws.
According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the market for the Company’s securities exhibited manipulative or deceptive activities; (2) the Company’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and PixarBio’s current and prospective development efforts lacked veracity; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Apple Turns 50: From Garage Startup to AI Crossroads
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 



